Non-alcoholic Fatty Liver Diseases (NAFLD) Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
Conditions: Dyslipidemias; Non-Alcoholic Fatty Liver Disease Interventions: Drug: LY3885125; Drug: Placebo Sponsor: Eli Lilly and Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials